Histone deacetylase inhibitors in cancer therapy
- PMID: 17461739
- DOI: 10.1517/13543784.16.5.659
Histone deacetylase inhibitors in cancer therapy
Abstract
Histones are a family of nuclear proteins that interact with DNA, resulting in DNA being wrapped around a core of histone octamer within the nucleosome. Acetylation/deacetylation of histones is an important mechanism that regulates gene expression and chromatin remodeling. Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic drugs that regulate gene expression by enhancing the acetylation of histones, and thus inducing chromatin relaxation and altering gene expression. HDAC inhibitors have been shown in preclinical studies to have potent anticancer activities. A range of structurally diverse HDAC inhibitors have been purified as natural products or synthetically produced. Due to the promising preclinical activity of these agents, numerous clinical trials have been initiated. In this review, the results of published data of single agent and combination trials of these drugs are reviewed, with a focus on dosing, scheduling and toxicity. Although still early in drug development, there is a picture that is starting to develop as to the common toxicities and which tumors seem to be the most susceptible to this class of drugs.
Similar articles
-
Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.Curr Drug Metab. 2007 May;8(4):383-93. doi: 10.2174/138920007780655397. Curr Drug Metab. 2007. PMID: 17504226 Review.
-
Epigenetic therapy of cancer with histone deacetylase inhibitors.J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937. J Cancer Res Ther. 2014. PMID: 25313724 Review.
-
Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.Curr Protein Pept Sci. 2018;19(3):333-340. doi: 10.2174/1389203718666170106101133. Curr Protein Pept Sci. 2018. PMID: 28059044 Review.
-
Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Cancer Chemother Pharmacol. 2013 Nov;72(5):935-52. doi: 10.1007/s00280-013-2223-9. Epub 2013 Sep 14. Cancer Chemother Pharmacol. 2013. PMID: 24036844 Review.
-
Histone deacetylase inhibitors: current status and overview of recent clinical trials.Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000. Drugs. 2009. PMID: 19747008 Review.
Cited by
-
Trials with 'epigenetic' drugs: an update.Mol Oncol. 2012 Dec;6(6):657-82. doi: 10.1016/j.molonc.2012.09.004. Epub 2012 Oct 6. Mol Oncol. 2012. PMID: 23103179 Free PMC article. Review.
-
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 May;125(2):367-71. doi: 10.1016/j.ygyno.2012.02.019. Epub 2012 Feb 21. Gynecol Oncol. 2012. PMID: 22366594 Free PMC article. Clinical Trial.
-
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3. Future Med Chem. 2012. PMID: 22416777 Free PMC article. Review.
-
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.Front Pharmacol. 2013 Apr 15;4:44. doi: 10.3389/fphar.2013.00044. eCollection 2013. Front Pharmacol. 2013. PMID: 23596417 Free PMC article.
-
Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells.Clin Epigenetics. 2010 Sep;1(1-2):45-54. doi: 10.1007/s13148-010-0007-1. Epub 2010 Jul 27. Clin Epigenetics. 2010. PMID: 22704088 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
